Project Search

The clinical development of Inflammatory Bowel Diseases (IBD) therapeutics is challenged by the natural waxing and waning of the disease to create large placebo effects that mask clinical outcome. Identifying reliable clinical biomarkers would enable more effective assessment of disease activity in clinical trials and would enable the design of individualized treatment strategies in the future. The project goal was to develop clinical diagnostics that would indicate disease state and response to EP4 agonist treatment in model systems, towards successful development of an EP4 agonist in clinical trials and in personalizing more effective therapies for patients suffering from IBD. The project was closed-out due to an inability to secure a license for the most promising EP4 agonist and the long timelines associated with clinical sample collection.